GlassScriptPhysician profile
Grace Lorena Honles
NPI 1578582854
$5,990.00
in general payments reported to CMS, 2019-2025
41 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $748 · 2021: $363 · 2022: $289 · 2023: $780 · 2024: $1,566 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.09 |
| Education | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $678.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $626.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $540.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $488.86 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.31 | 2019-2025 | Jardiance, Trijardy Xr |
| Novo Nordisk INC | $419.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $383.46 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $291.64 | 2022-2024 | Qelbree, Qelbree |
| Astellas Pharma US INC | $229.64 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $209.11 | 2019-2025 | Trintellix |
| Allergan, INC. | $203.63 | 2019-2020 | |
| Genentech USA, INC. | $146.74 | 2019-2020 | |
| Abbott Laboratories | $143.28 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Therapeuticsmd, INC. | $114.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.22 | 2022-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $90.09 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $80.05 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.64 | 2019-2023 | Xifaxan |
| Dynavax Technologies Corporation | $73.36 | 2019-2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $59.52 | 2022 | |
| Irhythm Technologies, INC. | $58.12 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Cranial Technologies, INC | $56.34 | 2023 | Doc Band |
| Medtronic, INC. | $46.07 | 2021 | |
| Sumitomo Pharma America, INC. | $45.42 | 2025 | Gemtesa |
| Amgen INC. | $37.77 | 2023-2024 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $35.43 | 2025 | Jornay Pm |
| Organon LLC | $34.27 | 2022 | |
| Merck Sharp & Dohme LLC | $33.61 | 2022-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Shire North American Group INC | $30.55 | 2019 | |
| Neos Therapeutics, LP | $27.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.90 | 2023 | Dupixent |
| Amneal Pharmaceuticals LLC | $24.67 | 2019 | |
| Corium, LLC | $23.33 | 2024 | Azstarys |
| Dexcom, INC. | $21.81 | 2025 | Dexcom G6 Transmitter |
| Alk-Abello, INC | $19.45 | 2022 | |
| Array Biopharma INC | $16.79 | 2023 | Paxlovid, Comirnaty, Prevnar 20 |
| Nevro Corp. | $15.76 | 2023 | Senza |
| Kaleo, INC. | $14.29 | 2019 | |
| Paragon 28, INC. | $14.18 | 2021 | |
| Mannkind Corporation | $13.35 | 2019 | |
| Circassia INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Honles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.